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Abstract
SHARPIN (Shank-Associated RH Domain-Interacting Protein) is a component of the linear
ubiquitin chain assembly complex (LUBAC), which enhances TNF-induced NF-κB activity.
SHARPIN-deficient (Sharpincpdm/cpdm) mice display multi-organ inflammation and chronic
proliferative dermatitis (cpdm) due to TNF-induced keratinocyte apoptosis. In cells, SHAR-
PIN also inhibits integrins independently of LUBAC, but it has remained enigmatic whether
elevated integrin activity levels in the dermis of Sharpincpdm/cpdm mice is due to increased
integrin activity or is secondary to inflammation. In addition, the functional contribution of
increased integrin activation to the Sharpincpdm/cpdm phenotype has not been investigated.
Here, we find increased integrin activity in keratinocytes from Tnfr1-/- Sharpincpdm/cpdm dou-
ble knockout mice, which do not display chronic inflammation or proliferative dermatitis, thus
suggesting that SHARPIN indeed acts as an integrin inhibitor in vivo. In addition, we present
evidence for a functional contribution of integrin activity to the Sharpincpdm/cpdm skin pheno-
type. Treatment with an integrin beta 1 function blocking antibody reduced epidermal hyper-
proliferation and epidermal thickness in Sharpincpdm/cpdm mice. Our data indicate that, while
TNF-induced cell death triggers the chronic inflammation and proliferative dermatitis,
absence of SHARPIN-dependent integrin inhibition exacerbates the epidermal hyperproli-
feration in Sharpincpdm/cpdm mice.
Introduction
Mice that lack the multifunctional adaptor protein SHARPIN (Sharpincpdm/cpdm) display
progressive multi-organ inflammation, which most prominently manifests with chronic eosino-
philic hyperproliferative dermatitis characterized by skin thickening, keratinocyte hyperproli-
feration and severe inflammation [1,2], which are characteristics of psoriasiform dermatitis.
Importantly, these pathological features in the skin are cell autonomous, as Sharpincpdm/cpdm
grafts on wild type mice maintain the inflammatory phenotype [3]. As an important component
of the Linear Ubiquitination Assembly Complex (LUBAC) [4–6], SHARPIN regulates canonical
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NF-κB (Nuclear factor-kappaB) signaling downstream of several receptors, such as Tumor
Necrosis Factor receptor (TNFR) [7], Toll-like receptor 2 [8], Toll-like receptor 3 [9], Interleu-
kin1 receptor [4–6] and CD40 [5,10]. The role of NF-κB in the skin epidermis is controversial as
some studies point to a pivotal role for NF-κB signaling in restraining epidermal growth (for
example [11–13]), while other studies suggest that NF-κB signaling does not regulate develop-
ment and differentiation of the epidermis (such as [14,15]). Importantly, crosses between Shar-
pincpdm/cpdm mice and Tnf-/- (Tnftm1Jods) or Tnfr1-/- (Tnfrsf1atm1Imx) mice almost fully rescue the
inflammatory and dermatitis phenotypes of Sharpincpdm/cpdm mice [6,16,17], although other phe-
notypes were not rescued, such as abnormal leukocyte cell count, the absence of Peyer’s patches
and absence of marginal zones in spleen [6,16]. Mechanistically, an increase in TNF-induced
keratinocyte apoptosis in the absence of LUBAC-mediated NF-kB signaling drives the systemic
inflammation and hyperproliferative dermatitis in Sharpincpdm/cpdm mice [6,16,17].
Integrins are the major cell adhesion receptors that mediate the interaction of a cell with
the surrounding extracellular matrix, including the basement membrane. Binding of integrins
to extracellular ligands triggers a conformational change in integrin structure that allows
recruitment of a plethora of cellular factors resulting in activation of several signaling pathways
[18]. SHARPIN acts as an integrin inhibitor through binding to the integrin cytoplasmic
domain, preventing the recruitment of integrin activating proteins and supporting the integrin
inactive conformation [19]. Functionally, SHARPIN-mediated integrin inhibition regulates
cell adhesion and migration [19], as well as lymphocyte detachment during transmigration
[20]. Importantly, SHARPIN plays mutually exclusive roles in regulating integrins and
LUBAC such that SHARPIN inhibits integrins independent of LUBAC [21].
Deregulated integrin activity is implicated in many human pathological conditions, includ-
ing immune diseases, skin blistering, bleeding disorders, and cancer [18]. In the skin, integrin
expression is predominantly confined to the basal keratinocytes that anchor the epidermis to
the basal lamina [22,23]. Transgenic mice overexpressing integrin beta 1 (Itgb1) in the supra-
basal layer of the epidermis (Tg(Itgb1)0869Fmw) exhibit epidermal hyperproliferation,
perturbed keratinocyte differentiation and skin inflammation [24], which resembles the Shar-
pincpdm/cpdm phenotype. Furthermore, integrin blocking therapies have been shown to alleviate
psoriasis in mice [25] and in human patients [26]. These data suggest that increased integrin
activation in Sharpincpdm/cpdm mice may contribute to the dermatitis phenotype. We have pre-
viously demonstrated increased Itgb1 activity in the basal layer of the epidermis of Shar-
pincpdm/cpdm mice [19]. However, whether this was due to the absence of SHARPIN-mediated
integrin inhibition or secondary to the chronic inflammation-driven proliferative dermatitis
has remained unclear.
Using Tnfr1-/- Sharpincpdm/cpdm double knockout mice we now present data suggesting that
SHARPIN acts as an integrin inhibitor in vivo also in the absence of chronic inflammation. In
addition, we demonstrate that Itgb1 inhibition with a function blocking antibody alleviates the
excessive proliferation and apoptosis observed in Sharpincpdm/cpdm epidermis, but does not
ameliorate the chronic and systemic inflammation in Sharpincpdm/cpdm mice, suggesting that
increased integrin activity in the absence of SHARPIN exacerbates the hyperproliferative skin
phenotype in Sharpincpdm/cpdm mice.
Results
Itgb1 activation is elevated in basal keratinocytes from Tnfr1-/-
Sharpincpdm/cpdm mice with normal epidermal thickness
We previously showed increased levels of active Itgb1 in the basal layer of the epidermis of
Sharpincpdm/cpdm mouse skin [19], consistent with SHARPIN-mediated integrin inhibition.
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However, the increase in integrin activation could be secondary to the chronic inflammation-
driven proliferative dermatitis in Sharpincpdm/cpdm mice. To address whether SHARPIN truly
acts as an integrin inhibitor in vivo, we made use of the Tnfr1-/- Sharpincpdm/cpdm double knock-
out mice, in which the skin thickening (Fig 1A), chronic inflammation and dermatitis, typical
to Sharpincpdm/cpdm mice, are absent [16,17]. This allowed us to investigate the role of SHAR-
PIN in vivo without the consequences of increased Tnfr1-induced inflammation and apoptosis
in Sharpincpdm/cpdm skin.
Labeling skin sections from Tnfr1+/+ Sharpin+/?, Tnfr1+/+ Sharpincpdm/cpdm, Tnfr1-/- Shar-
pin+/? and Tnfr1-/- Sharpincpdm/cpdm mice with an antibody that specifically recognizes active
Itgb1 [9EG7; [27]] confirmed the increased active Itgb1 levels in Tnfr1+/+ Sharpincpdm/cpdm epi-
dermis [19] but also revealed elevated Itgb1 activity in Tnfr1-/- Sharpincpdm/cpdm basal keratino-
cytes despite normal skin thickness (Fig 1A).
To analyze this observation quantitatively and without the interference of high dermal
Itgb1 activity (Fig 1A), we isolated keratinocytes from the epidermal layer of Tnfr1+/+ Shar-
pincpdm/cpdm, Tnfr1-/- Sharpin+/? and Tnfr1-/- Sharpincpdm/cpdm mice, and investigated Itgb1
activity specifically in basal cell layer keratinocytes that also express Integrin alpha 6 (Itga6,
also known as CD49f; Fig 1B) (see Methods for details). In order to distinguish basal keratino-
cytes by flow cytometry, any residual cells expressing lineage markers for leukocytes [CD45,
Protein Tyrosine Phosphatase, Receptor Type C (PTPRC)] or endothelial cells [CD31, Platelet
And Endothelial Cell Adhesion Molecule 1 (PECAM1)] were gated out by flow cytometry, and
cells expressing Itga6 were further analyzed for binding active Itgb1 (9EG7) or total Itgb1
(HMβ1–1) antibodies (Fig 1C). Quantification of these data showed that the amount of active
Itgb1 on the surface of the double knockout Tnfr1-/- Sharpincpdm/cpdm basal keratinocytes was
indeed significantly increased compared to Tnfr1-/- Sharpin+/? keratinocytes, although it was
lower than in the hyperproliferative Tnfr1+/+ Sharpincpdm/cpdm cells (Fig 1D). The total Itgb1
levels were not significantly altered even though total Itgb1 levels seem elevated in Tnfr1+/+
Sharpincpdm/cpdm basal keratinocytes (Fig 1E). Importantly, FACS experiments with primary
keratinocytes from four individual mice showed that staining with the 9EG7 antibody results
in approximately 6 fold higher signals than isotype control (Panel A and B in S1 Fig). Alto-
gether, these data suggest that increased Itgb1 activity in Sharpincpdm/cpdm mice is not solely
due to chronic inflammation and proliferative dermatitis but that SHARPIN functions as an
integrin inhibitor in vivo.
Itgb1 inhibition ameliorates the epidermal hyperproliferation phenotype
in Sharpincpdm/cpdm mice
Given that SHARPIN indeed inhibits integrin activity in mouse epidermis (Fig 1), we hypothe-
sized that the increased Itgb1 activity might contribute to the Sharpincpdm/cpdm dermatitis phe-
notype. Since epidermal Itgb1 depletion is lethal [28], Sharpincpdm/cpdm and age- and gender-
matched control (Sharpin+/+ or Sharpin+/cpdm) mice were systemically treated with an Itgb1
function-blocking antibody or with PBS. Tnfr1-/- Sharpin+/? and Tnfr1-/- Sharpincpdm/cpdm mice
were not included in this experiment as they display a normal skin phenotype. As expected,
the epidermis of Sharpincpdm/cpdm mice was much thicker than in control treated mice (Fig
2A–2C). Interestingly, blocking Itgb1 function significantly reduced epidermal thickness in
Sharpincpdm/cpdm, but not in control mice (Fig 2A–2C), without significantly affecting dermal
thickness (Panel C in S1 Fig). From each animal the epidermal thickness was measured from
five individual tissue sections with two measurements per skin section, thus minimizing the
chances of recording experimental outliers. Importantly, plotting all data showed equal
Integrin beta 1 inhibition alleviates chronic hyperproliferative dermatitis in SHARPIN-deficient mice
PLOS ONE | https://doi.org/10.1371/journal.pone.0186628 October 17, 2017 3 / 14
Fig 1. Keratinocytes from Tnfr1-/- Sharpincpdm/cpdm double knockout mice have higher levels of active Itgb1. (A)
Representative frozen skin sections from 6 weeks old Tnfr1+/+ Sharpin+/?, Tnfr1+/+ Sharpincpdm/cpdm, Tnfr1-/- Sharpin+/? and
Tnfr1-/- Sharpincpdm/cpdm mice (n = 3 animals per genotype) stained for Keratin-14 (Krt14) and active Itgb1 (clone 9EG7).
Scale bars represent 50 μm. Arrows indicate the basal cell layer. (B) Representative frozen skin sections from 6 weeks old
Tnfr1-/- Sharpincpdm/cpdm mice stained for Krt14 (epidermis) and Itga6 (basal keratinocytes). Scale bars represent 10 μm.
(C) Primary keratinocytes were isolated from Tnfr1-/- Sharpin+/?, Tnfr1-/- Sharpincpdm/cpdm and Tnfr1+/+ Sharpincpdm/cpdm
mice and studied by flow cytometry. Live cells (FSC/SSC; left panel) were sorted for expression of Itga6 (CD49f) and
lineage (Lin) markers CD31 and CD45 (central panel). Cell surface expression of active Itgb1 (CD29; clone 9EG7) was
plotted (right panel) from the gated basal keratinocyte population (live, Itga6+Lin-). (D,E) Relative geometric mean
fluorescence intensities of (D) active Itgb1 (n = 6, 5 and 4 animals per genotype) and (E) total Itgb1 (n = 4, 4 and 3 animals
per genotype) cell surface staining on Tnfr1-/- Sharpin+/?, Tnfr1-/- Sharpincpdm/cpdm and Tnfr1+/+ Sharpincpdm/cpdm basal
keratinocytes sorted as in (C). Numerical data are mean ± s.e.m.
https://doi.org/10.1371/journal.pone.0186628.g001
Integrin beta 1 inhibition alleviates chronic hyperproliferative dermatitis in SHARPIN-deficient mice
PLOS ONE | https://doi.org/10.1371/journal.pone.0186628 October 17, 2017 4 / 14
Fig 2. Blocking Itgb1 activity ameliorates the chronic hyperproliferative dermatitis phenotype in
Sharpincpdm/cpdm mice. (A) Representative H&E-stained skin sections from Sharpin+/? and Sharpincpdm/cpdm
mice treated with PBS (control) or anti-Itgb1 (Itgb1 function blocking antibody). Arrows indicate the epidermis.
(B) Quantification of epidermal skin thickness from skin sections as depicted in (A) (n = 3 and 4 Sharpin+/?
animals and n = 5 and 5 Sharpincpdm/cpdm animals per control and anti-Itgb1, respectively; five individual tissue
sections were measured per animal with two measurements per skin section). Data from one out of two
experiments with similar results are shown. (C,D) Representative frozen skin sections from Sharpin+/? and
Sharpincpdm/cpdm mice treated with PBS (control) or anti-Itgb1, stained for Krt14 (C) or proliferation (Ki67) and
basal keratinocytes (Itga6) (D). (E) Quantification of epidermal proliferation from skin sections as depicted
in (D) (n = 2 Sharpin+/? and 3 Sharpincpdm/cpdm animals; 4–6 and 19–20 measurements per animal,
respectively). (F, G, H) Sharpin+/? and Sharpincpdm/cpdm mouse primary keratinocytes were isolated from 6
weeks old mice and SHARPIN expression (F) and cell proliferation rate (G) were evaluated by western
Integrin beta 1 inhibition alleviates chronic hyperproliferative dermatitis in SHARPIN-deficient mice
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variation between measurements and a large difference between experimental conditions
(Panel D in S1 Fig).
Staining for the proliferation marker Ki67 indicated that inhibition of Itgb1 in Shar-
pincpdm/cpdm mice reduced the number of proliferating epidermal cells (Fig 2D and 2E), sug-
gesting that Itgb1 inhibition reduces keratinocyte proliferation. To determine if the reduced
keratinocyte proliferation is an autonomous effect of Itgb1 inhibition, we cultured Shar-
pincpdm/cpdm and Sharpin+/? primary mouse keratinocytes, isolated from 6 weeks old mice (Fig
2F and 2G; Panel E in S1 Fig), and evaluated the effect of either Itgb1 function blocking anti-
body or isotype control antibody on cell proliferation (Fig 2H). While Sharpincpdm/cpdm kera-
tinocytes demonstrated comparable or even higher proliferation rate than Sharpin+/? cells in
vitro (Fig 2G), integrin inhibition with the Itgb1 function blocking antibody significantly
reduced both Sharpincpdm/cpdm and Sharpin+/? primary keratinocyte proliferation (Fig 2H),
showing that the Itgb1 blocking antibody inhibits keratinocyte proliferation autonomously
and suggesting that amelioration of the chronic proliferative dermatitis (Fig 2A–2C) is, at
least partly, linked to decreased keratinocyte proliferation.
Itgb1 inhibition does not reduce the chronic inflammation in
Sharpincpdm/cpdm mice
Chronic inflammation in Sharpincpdm/cpdm mice is characterized by enhanced infiltration of
immune cells to many tissues including the skin [1,29], as well as increased numbers of white
blood cells in the peripheral blood [30]. Interestingly, leukocyte (CD45+; Fig 3A and 3B), mac-
rophage (F4/80+; Fig 3C and 3D) and mast cell (Toluidine blue+; Fig 3E and 3F) infiltration
into the dermis of Sharpincpdm/cpdm mice was not affected by the Itgb1 function-blocking anti-
body, indicating that inflammation was not reduced. Also, the increased numbers of white
blood cells in the peripheral blood of Sharpincpdm/cpdm mice remained elevated or even
increased further upon Itgb1 inhibition (Panel A in S2 Fig), further suggesting that the
chronic inflammation in Sharpincpdm/cpdm mice does not depend on Itgb1.
Elevated keratinocyte apoptosis in Sharpincpdm/cpdm mouse skin is
partially rescued by Itgb1 inhibition
While the chronic proliferative dermatitis of Sharpincpdm/cpdm mice fully depends on TNF-
induced keratinocyte apoptosis [6,16,17], Itgb1 antibody treatment did not affect the previ-
ously reported [31] elevation of Tnf expression levels in the Sharpincpdm/cpdm skin (Panel B and
C in S2 Fig), suggesting that altered Tnf expression levels are not mediating the effects of the
Itgb1 antibody treatment. However, systemic Itgb1 antibody treatment reduced the increased
apoptosis in Sharpincpdm/cpdm epidermis (Fig 4A and 4B). Since Tnf levels remained high
despite Itgb1 antibody treatment (Panel B and C in S2 Fig), the reduction in apoptotic cell
numbers could rather be related to the decreased proliferation as keratinocyte apoptosis bal-
ances cell proliferation to control epidermal thickness [32]. These data suggest that inhibition
of integrin activity in Sharpincpdm/cpdm mice with an anti-Itgb1 antibody ameliorates the chain
reaction leading to hyperproliferative dermatitis in the absence of SHARPIN.
blotting and Cell Proliferation Reagent WST-1, respectively. (H) Relative proliferation of Sharpincpdm/cpdm and
Sharpin+/? keratinocytes was quantified after 2 days incubation with 10 μg/ml anti-Itgb1 antibody or isotype
IgG control (n = 7 animals per genotype). Scale bars are 50 (A) and 20 μm (C,D). All numerical data are
mean ± s.e.m.
https://doi.org/10.1371/journal.pone.0186628.g002
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Discussion
The multifunctional adaptor protein SHARPIN regulates integrins [19,20] and TNF-induced
NF-kB signaling [4–6], but whether defective integrin regulation also contributes to the
Fig 3. Blocking Itgb1 activity does not inhibit inflammation in Sharpincpdm/cpdm mice. (A, C, and E)
Representative skin sections from Sharpin+/? and Sharpincpdm/cpdm mice treated with PBS (control) or anti-Itgb1
antibody, and stained for (A) leukocytes (CD45), (C) macrophages (F4/80) and Krt14, or (E) mast cells (Toluidine
blue). Nuclei were stained with DAPI (A, C), red arrows indicate toluidine blue positive mast cells (E). Scale bars
represent 20 μm (A, C) and 50 μm (E). (B, D, and F) Quantification of (B) dermal leukocyte infiltration (n = 3 or 4
animals; 10–18 measurements per animal), (D) dermal macrophage infiltration (n = 3 or 4 animals; 9–19
measurements per animal) and (F) mast cell infiltration (amount of mast cells/skin section; n = 4 or 5 animals with 10
measurements per animal) from skin sections as depicted in (A, C, and E). Numerical data are mean ± s.e.m.
https://doi.org/10.1371/journal.pone.0186628.g003
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Sharpincpdm/cpdm skin phenotype has remained unknown [33]. This study now demonstrates
that Itgb1 inhibition in Sharpincpdm/cpdm mice significantly reduces epidermal proliferation
and apoptosis, suggesting a modulatory role for integrins in the chronic proliferative dermati-
tis phenotype.
Through direct interaction with the integrin cytoplasmic domain SHARPIN inhibits integ-
rin activity, which plays a role in cell adhesion and migration [19,20]. Consistently, increased
levels of active Itgb1 were observed in the epidermis of Sharpincpdm/cpdm mice [19]. However,
as Sharpincpdm/cpdm mice suffer from chronic proliferative dermatitis, it has remained unclear
whether increased integrin activity in the Sharpincpdm/cpdm epidermis is due to lack of SHAR-
PIN or merely a side effect of the dermatitis. Using Tnfr1-/-Sharpincpdm/cpdm double knock out
mice [6] we now report that Itgb1 activity is also increased in basal Tnfr1-/- Sharpincpdm/cpdm
keratinocytes in the absence of proliferative dermatitis, supportive of a direct role for SHAR-
PIN in integrin inhibition in vivo. The Tnfr1-/- Sharpincpdm/cpdm mice and other double knock
out mice that rescue the Sharpincpdm/cpdm inflammatory phenotype [6,16,17] are excellent tools
to dissect which in vivo functions of SHARPIN are a side effect of the inflammatory phenotype
and which phenotypes are independent of the inflammation. In addition, as Tnfr1-/- Shar-
pincpdm/cpdm mice have a considerably longer life span than Sharpincpdm/cpdm mice, which need
to be sacrificed by 8 weeks due to severe skin inflammation, these double knock out mice pro-
vide means to address whether SHARPIN has important functions later in development and
in the development of diseases, such as cancer.
Sharpincpdm/cpdm mice display skin thickening (hyperkeratosis), increased keratinocyte pro-
liferation and apoptosis, as well as increased inflammatory cell infiltration [1,2,29]. The pheno-
type has been shown to originate from defective NF-kB signaling and increased apoptosis
Fig 4. Elevated keratinocyte apoptosis in Sharpincpdm/cpdm mouse skin is partially rescued by Itgb1 inhibition. (A) Representative frozen skin
sections from Sharpin+/? and Sharpincpdm/cpdm mice treated with PBS (control) or anti-Itgb1, stained for apoptotic cells [cleaved caspase-3 (Casp3)]. Red
arrows indicate cleaved caspase-3 positive apoptotic cells. Scale bars represent 20 μm. (B) Quantification of epidermal apoptosis from skin sections as
depicted in (A) (n = 4 Sharpin+/? and 3 Sharpincpdm/cpdm animals; 13–18 measurements per animal). Numerical data are mean ± s.e.m.
https://doi.org/10.1371/journal.pone.0186628.g004
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induction in response to Tnfr1 activation in keratinocytes, as crosses between Sharpincpdm/cpdm
mice and Tnf-/- or Tnf1r-/- mice fully rescued the chronic proliferative dermatitis [6,16,17].
Transgenic mice with suprabasal expression of Itgb1 displayed similar chronic proliferative
dermatitis with deregulated keratinocyte proliferation and skin inflammation, although apo-
ptosis was not significantly affected [24]. In Sharpincpdm/cpdm mice, however, the increased
Itgb1 activity was primarily observed in basal keratinocytes negative for Keratin-10 or involu-
crin expression [19]. Our study now shows that inhibition of Itgb1 in Sharpincpdm/cpdm mice
decreases both keratinocyte proliferation and apoptosis. Importantly, inflammation was not
affected, suggesting that the cause of the alleviated phenotype is different from that in the
aforementioned Tnf-/- Sharpincpdm/cpdm and Tnfr1-/- Sharpincpdm/cpdm double knockout mice.
Thus, while Tnf-induced keratinocyte death drives chronic proliferative dermatitis in Shar-
pincpdm/cpdm mice, increased Itgb1 activity appears to exacerbate the hyperproliferative skin
phenotype, consistent with the important role of Itgb1 in keratinocyte proliferation [34].
Recently, SHARPIN was also shown to bind and inhibit the T cell receptor (TCR) in a
LUBAC-independent fashion, thereby playing an intrinsic role in the generation of regulatory
T cells (Treg cells) [35]. Importantly, transfer of wild type Treg cells into Sharpincpdm/cpdm mice
considerably alleviated their systemic inflammation [35]. These and our data together show
that, though chronic inflammation in Sharpincpdm/cpdm mice is triggered by Tnf-mediated apo-
ptosis [6,16,17], other regulatory roles of SHARPIN contribute to different aspects of the com-
plex Sharpincpdm/cpdm phenotype.
In summary, our data suggest that Sharpin functions as an integrin inhibitor in vivo and
that integrins contribute to the chronic proliferative dermatitis phenotype in Sharpincpdm/cpdm
mice. We therefore postulate that different aspects of the complex Sharpincpdm/cpdm phenotype,




The C57BL/KaLawRij-Sharpincpdm/RijSunJ mouse strain (Stock No: 007599 |) with a sponta-
neous mutation leading to the complete loss of SHARPIN protein [1,2] was acquired from
The Jackson Laboratory (Bar Harbor, ME). The colony was maintained in heterozygote breed-
ing and genotyped for the Sharpincpdm/cpdm mutation to obtain Sharpincpdm/cdpm homozygous
mice and littermate control mice (Sharpin+/+ or Sharpin +/cpdm) for experiments. DNA was
extracted with KAPA Mouse Genotyping Kit (KK7302) and the Sharpincpdm mutation detected
using 40x genotyping assay mix (TaqMan SNP Genotyping Assays, 5793982, Applied Biosys-
tems) and TaqMan Universal PCR Master Mix. Tnfrsf1atm1Imx Sharpincpdm/cdpm mice [16]
(Tnfrsf1atm1Imx Stock No: 003242; hereafter called Tnfr1-/-), obtained from Prof. H. Walczak,
were also maintained in heterozygote breeding. PCR amplification was used for detection of
the deletion in Tnfr1 gene in somatic DNA. Age-matched mice were used in all the experi-
ments described here. As both male and female Sharpincpdm/cdpm mice develop the same
symptoms and we have to perform heterozygous breedings, both genders were used in the
experiments.
Mice were housed in standard conditions (12-h light/dark cycle) with food and water avail-
able ad libitum. The viability, clinical signs and behaviour of the mice were monitored daily.
For euthanasia, cervical dislocation was used in conjunction with CO2. All animal experiments
were ethically assessed and authorised by the National Animal Experiment Board and in
accordance with The Finnish Act on Animal Experimentation (Animal licence numbers 7522/
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04.10.03/2012, ESAVI-5588-04.10.07–2014, ESAVI-9339-04.10.07–2016) and The Jackson
Laboratory Animal Care and Use Committee (approval number 07005).
Antibody treatment of mice
Five pairs of 5-week old gender-matched Sharpincpdm/cpdm and Sharpin+/? littermates were
injected intraperitoneally with 0.1 ml of 0.05 mg/ml function-blocking anti-mouse ITGB1
antibody (LEAF™ purified anti-mouse CD29 Armenian hamster IgG (clone HMB1-1, Biole-
gend) or PBS twice a week. Mice were injected for a total of 3 weeks (6 injections) and then
euthanized by CO2 asphyxiation. Complete necropsies were performed as described [36]. Skin
was collected in Fekete’s acid-alcohol-formalin. Dorsal skin was also collected in 4% parafor-
maldehyde for immunofluorescence or fresh frozen for IHC. Blood was collected in EDTA
tubes for analysis using the ADVIA 120 Hematology System (Siemens Healthcare Global).
Four pairs of 5-week old littermates injected with 0.1 ml of 0.5 mg/ml anti-mouse CD29 anti-
body or Armenian hamster IgG negative control antibody (Biolegend) showed highly similar
results.
Antibodies
The antibodies used in this study are LEAF™ purified Anti-mouse CD29 Armenian hamster
IgG (Biolegend; HMB1-1), Armenian hamster IgG negative control (Biolegend), Itga6 (Sero-
tec; NKI-GoH3; 1:200 in immunohistochemistry of frozen sections (IHC-Fr), cleaved Casp3
(Cell Signaling; 5A1E; 1:400 IHC-Fr), Ki67 (Abcam; ab66155; 1:300 IHC-Fr), CD45 (PTPRC)
(BD Pharmingen; 30-F11; 1:250 in IHC-Fr, 1:200 in FACS), F4/80 (CiteAb; MF48020; 1:50 in
IHC-Fr), Krt14 (Biosite; PRB-155P; 1:600 in IHC-Fr), Tnf (Abcam; ab6671; 1:200 in IHC-Fr),
CD31 (PECAM1) (Biolegend; 1:50 in FACS), active Itgb1 (BD Pharmingen; 9EG7; 1:100 in
IHC-Fr, 1:50 in FACS), total Itgb1 (CD29-Alexa Fluor 647) (Biolegend; HMβ1–1; 1:50 in
FACS), CD49f (Itga6) (Biolegend; GoH3; 1:20 in FACS), SHARPIN (Proteintech; 1:1000 WB),
Krt14 (Covance; 1:1000 WB), Vimentin (D21H3, Cell Signalling; 1:1000 WB), GAPDH (5G4
Mab 6C5, Hytest; 1:1000 WB), DyLight 680- or 800-conjugated IgGs (Thermo Scientific;
1:5000 WB) and AlexaFluor 488/568/647-conjugated secondary Igs (Invitrogen; 1:300 in
IHC-Fr and FACS).
Immunofluorescence
O.C.T. (Sakura) embedded frozen skin sections were fixed (4% paraformaldehyde), quenched
(100mM glycine in PBS), and blocked/permeabilized (2% BSA, 0.1% Triton X100 in PBS).
Samples were labeled with primary antibodies (1 hour at RT in 2% BSA in PBS), washed three
times and labeled with fluorescent secondary antibodies. After washes, samples were mounted
in Vectashield mounting medium (Vector Laboratories) and viewed using a 20x objective on
either a 3i Marianas Spinning disk confocal microscope (Intelligent Imaging Innovations) or
Zeiss Axiovert 200M with Yokogawa CSU22 spinning disk confocal microscope unit with
Hamamatsu Orca ER CCD camera (Hamamatsu Photonics K.K.). Images were processed and
quantified using Fiji image analysis software [37].
Isolation and culture of mouse primary keratinocytes
6–8 weeks old littermate mice were sacrificed, dorsal skin was shaved and a piece of dorsal
skin (1.5 cm x 1.5 cm) was harvested in cold PBS. Tissue was cut further to smaller pieces,
rinsed with Hank’s Balanced Salt Solution without Ca2+ and Mg2+ (HBSS; Sigma), and incu-
bated overnight in 0,25% porcine trypsin (Sigma) in HBSS at +4˚C on a shaker. Next day, the
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dermis was removed with forceps, the remaining epidermis was chopped with a scalpel and
incubated in 0.2% Collagenase XI (Sigma) at 37˚C incubator for 30 min. Keratinocytes were
dissociated from the tissue by pipetting the suspension every 5–10 minutes. Keratinocytes
were filtered through a cell strainer (70 μm; BD Biosciences). Finally, cells were incubated with
20 U/ml DNase I (Roche) for 5 min on ice and spun down.
Primary keratinocytes were cultured on a 6-well plate coated with 20 μg/ml Collagen Type I
from rat tail (Merck Millipore) in FAD medium [Dulbecco’s Modified Eagle’s Medium:Ham’s
F12 Nutrient Mixture (GIBCO) 3.5:1.1] supplemented with 10% fetal bovine serum (FBS)
(chelated using Bio-Rad Chelex1 100 Chelating Resin), 5 μg/ml insulin, 100 pM choleratoxin,
10 ng/ml epidermal growth factor (EGF), 100 U/ml sodium pyruvate, 100 μg/ml penicillin-
streptomycin and 0.5 μg/ml hydrocortisone (all from Sigma Aldrich if not otherwise men-
tioned) in 5% CO2 and 32˚C.
Keratinocyte proliferation assay
Equal amounts of primary mouse keratinocytes were plated on 96-well plates coated with
20 μg/ml rat tail Collagen Type I. One day after seeding, the keratinocytes were treated with
10 μg/ml anti-Itgb1(Anti-mouse CD29 Armenian hamster IgG) or isotype IgG control anti-
body. Theamount of cells) in each well was quantified with Cell Proliferation Reagent WST-1
(Roche, Sigma Aldrich) according to the manufacturer’s instructions and a BioTek Synergy
H1 Hybrid Multi-Mode Microplate Reader. The relative proliferation was calculated by nor-
malizing the amount of cells in each time point to day zero (Fig 2G) or by subtracting the
amount of cells at day zero from the value at day two (corrected cell amount), followed by nor-
malizing to the corrected cell amount of IgG control. A minimum of two wells per keratino-
cyte primary cell line were analysed per time point.
Flow cytometry
The active conformation specific Itgb1 antibody (clone 9EG7, BD Pharmingen) was concen-
trated with an Amicon1 Ultra filter centrifugation and directly conjugated to Alexa Fluor 647
with APEX1 antibody labelling kit (Thermo Fischer Scientific). Cells were fixed with 2% para-
formaldehyde in PBS for 10 min at RT, after which they were centrifuged and washed with
cold Tyrodes buffer (10 mM Hepes-NaOH pH 7.5, 137 mM NaCl, 2.68 mM KCl, 0.42 mM
NaH2PO4, 1.7 mM MgCl2, 11.9 mM NaHCO3, 5 mM glucose). The cells were stained with
directly fluorochrome-conjugated antibodies [CD31-Pacific Blue (PECAM1), CD45-Pacific
Blue (PTPRC), CD49f-488 (Itga6, Clone: GoH3) (all from BioLegend), and CD29-AlexaFluor
647 or active Itgb1 (clone 9EG7) -647] in 100 μl Tyrodes for 30 min RT, washed with Tyrodes
and resuspended in PBS. Filtered cells were analysed using BD LSRFortessa (BD Biosciences)
and FlowJo analysis software (Tree Star).
Western blotting
Protein content in primary mouse keratinocytes was analysed by immunoblotting using stan-
dard western blotting techniques and the Odyssey LICOR imaging system.
Statistical analysis
All statistical analyses were performed using GraphPad Prism (GraphPad Software, San Diego,
USA). Normal distribution was assumed for the data and unpaired Student’s t-test was used
for all experiments. A p< 0.05 was considered significant.
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Supporting information
S1 Fig. Experiments in (C-E) show data from Sharpin+/? and Sharpincpdm/cpdm mice treated
with PBS (control) or anti-Itgb1 (Itgb1 function blocking antibody). (A,B) FACS analysis
(A) and quantification (B) of active Itgb1 (10 μg/ml Rat Anti-Mouse CD29, Clone 9EG7) label-
ling specificity compared to isotype IgG control (10 μg/ml Rat IgG2a, κ isotype control) in pri-
mary mouse keratinocytes using AlexaFluor647 conjugated anti-rat secondary antibody.
Samples were analyzed by flow cytometry at SSC/FSC and APC-A channels, and background
fluorescence was subtracted before normalization to Isotype IgG (mean +/-SEM; n = 4 mice).
(C) Quantification of dermal skin thickness from skin sections similar to those depicted in Fig
2A (n = 4 or 5 animals with 10 measurements per animal). (D) Dot plot of all individual mea-
surements of epidermal skin thickness from skin sections similar to those depicted in Fig 2A
(five individual tissue sections were measured per animal with two measurements per skin sec-
tion). The plot in Fig 2B shows averages per animal. (E) Krt-14 (marker for keratinocytes),
vimentin (marker for fibroblasts) and GAPDH expression levels in keratinocytes isolated from
Sharpin+/+, Sharpin+/- and Sharpincpdm/cpdm mice, as well as mouse embryonic fibroblast
(MEF). Keratinocyte isolation purity was evaluated by measuring the Krt14/vimentin ratio,
normalized to GAPDH, with MEFs serving as a control fibroblast cell line. Molecular weight
markers are indicated (KDa). All numerical data are mean ± s.e.m. Scale bars represent 20 μm.
(TIF)
S2 Fig. Blocking Itgb1 activity does not affect inflammation or Tnf levels in Sharpincpdm/cpdm
mice. Experiments show data from Sharpin+/? and Sharpincpdm/cpdm mice treated with PBS (con-
trol) or anti-Itgb1 (Itgb1 function blocking antibody). (A) Quantification of immune cell popu-
lations from peripheral blood. WBC, white blood cells; LUC, large unstained cells. (B,C)
Representative skin sections stained for Tnf and nuclei (DAPI) (B) and quantification of dermal
Tnf levels (C) (n = 2 and 4 Sharpin+/? animals in control and anti-CD29 group, respectively, and
5 in each Sharpincpdm/cpdm group, 10–40 measurements per animal). Dotted line marks the base-
ment membrane. All numerical data are mean ± s.e.m. Scale bars represent 20 μm.
(TIF)
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